Evaluation of thyroid ablative therapy for ophthalmopathy of Graves' disease

Orbit

Volumn 15, Issue 3, 1996, Pages 187-196

  DeGroot, Leslie J ^a   Benjasuratwong, Yupin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antithyroid drugs; Cytotoxicity; Radioiodide; Thyroid ablation; Thyrotoxicosis

Indexed keywords

IODINE 131;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOCRINE OPHTHALMOPATHY; FEMALE; GRAVES DISEASE; HUMAN; MALE;

EID: 0029786716     PISSN: 01676830     EISSN: None     Source Type: Journal    
DOI: 10.3109/01676839609150236     Document Type: Article

References (19)

1. Loeb L, Friedman H. Exophthalmos produced by injections of acid extract of anterior pituitary gland of cattle. Proc Soc Exp Biol Med 1932; 29:648-650.
2. Albert A. The experimental production of exophthalmos in fundulus by means of anterior pituitary extracts. Endocrinology 1945; 37:389-406.
3. Kohn LD, Winand RJ. Structure of an exophthalmos-producing factor derived from thyrotropin by partial pepsin digestion. J Biol Chem 1975; 250:6503-6508.
4. Kodama K, Bandy-Dafoe P, Sikorska H, Bayly R, Wall JR. Demonstration of a circulating autoantibody against a soluble eye muscle antigen in Graves' ophthalmopathy. Lancet 1982; 2:1353-1356.
5. Kendall-Taylor P, Atkinson S, Holcombe M. A specific IgG in Graves' ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity. Br Med J 1984; 288:1183-1186.
6. Zhang Z-G, Medeiros-Neto G, Iacona A, Lima N, Hiromatsu Y, Salvi M, et al. Studies of cytotoxic antibodies against eye muscle antigens in patients with thyroid-associated ophthalmopathy. Acta Endocrinol 1989; 121:23-30.
7. Hiromatsu Y, Cadarso L, Salvi M, Wall JR. Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy. Autoimmunity 1990; 5:205-213.
8. Hiromatsu Y, Wang PW, Wosu L, How J, Wall JR. Mechanisms of immune damage in Graves' ophthalmopathy. Hormone Res 1987; 26:198-207.
9. DeGroot LJ, Larsen PR, Refetoff S, Stanbury JB. Graves' disease: complications. Ch 8 in: The Thyroid and its Diseases. 5th edn. New York: John Wiley & Sons, 1984; 462.
10. Wall JR. Autoimmunity and Graves' ophthalmopathy. In: Gorman C, Wall JR, Dyer JA (editors). The Eye and The Orbit in Thyroid Disease. New York: Raven Press, 1984; 103-119.
11. Wall JR, Salvi M, Bernard N. Eye disease and autoimmune thyroid disorders: mechanism for the association. In: Wall JR, How J (editors). Pathogenesis and Management of Graves' Ophthalmopathy. Contemporary Issues in Endocrinology and Metabolism. Oxford: Blackwell Scientific Publications Inc, 1990; 63-77.
12. Bauer FK, Catz B. Radioactive iodine therapy for progressive malignant exophthalmos. Acta Endocrinol 1966; 51:15-22.
13. Werner SC, Feind CR, Aida M. Graves' disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long-acting thyroid stimulator after operation. N Engl J Med 1967; 276:132-138.
14. Volpe R, Desbarats-Schonbaum M-L, Schonbaum E, Row V, Ezrin C. The effect of radioablation of the thyroid gland in Graves' disease with high levels of long-acting thyroid stimulator (LATS). Am J Med 1969; 46:217-226.
15. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Eng J Med 1992; 326:1733-1738.
16. 131I treatment protocols for Graves' disease. J Endocrinol Invest 1990; 13:111-118.
17. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989; 87; 70-73.
18. Fenzi G, Hashizume, K, Roudebush C, DeGroot LJ. Changes in thyroid stimulating immunoglobulins during antithyroid therapy. J Clin Endocrinol Metabol 1979; 48:572-576.
19. Soliman M, Kaplan EL, Abdel-Latif A, Scherberg N, DeGroot LJ. Does thyroidectomy, RAI therapy, or antithyroid drug treatment alter reactivity of patient's T cells to epitopes of thyrotropin receptor in autoimmune thyroid disease? J Clin Endocrinol Metabol 1995; 80:2312-2321.